Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2023-504477-21-00Phase 3Withdrawn
Phase 3, randomised, single-blind trial in well-being comparing Chloroprocaine 3% eye gel with Oxybuprocaine 0.4% eye drops (2 arms). Primary endpoint: Proportion of patients with successful conjunctival anesthesia in the right eye at 5 minutes after study product administration. Planned start Sep 2023; status: withdrawn.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2023-504477-21-00.